Genprex has entered an exclusive licensing agreement with the US University of Michigan for lung cancer therapy, Reqorsa.

Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it ...

REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of ... REQORSA's potential as a therapeutic treatment in combination ...

License includes Genprex's Reqorsa® Gene Therapy in Combination with ALK-Inhibitors for the Potential Treatment of ALK-Positive Lung ... pathways that cause replication and proliferation of ...

The relatively new paradigm of 'rationally targeted' cancer drug therapies ... HER2, MET and ALK interface with common downstream signaling pathways and 'addiction switching' can occur, either ...

Identifying gene mutations has paved the way for targeted lung cancer testing and therapies. For example, targeted drug treatment therapies are available, or in development, for the following gene ...

uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung cancer. These findings open the ... Genetic Signature May Predict Response ...

You may experience a high white blood cell count with lung cancer due to infections. Medications, such as chemotherapy, may also affect your white blood cell count. Lung cancer begins with lung ...